- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Medwin Healthcare introduces Shycocan to contain spread of COVID-19
This device is priced at 19,999 inclusive of 18 per cent GST, he added.
New Delhi : Medwin Healthcare on Tuesday announced the launch of a device which, it claimed, has the ability to contain the spread of coronavirus.
The device, Shycocan (Scalene Hypercharge Corona Canon), has been invented by Rajah Vijay Kumar who is Chairman & Chief Scientific Officer, Organization de Scalene and Scalene Cybernetics Ltd, Medwin Healthcare said in a statement.
The company is the international humanitarian agreement holder to manufacture and market Shycocan for India as well as for the entire South Asia, it added.
"Shycocan is proven to be 99.9 per cent effective in neutralising the Spike-Protein or S-protein that are present in coronavirus...We have received approvals from the US Food and Drug Administration (USFDA) and the European Union Confirmite Europenne (CE)," Kumar said.
The product has fulfilled the conditions laid down by European Union- CE and it is market enabled as per the USFDA''s enforcement discretion guidance during the COVID-19 Public Health Emergency, the statement said.
"Medwin Healthcare will manufacture and market this device not only for the people in India but for the world at large," Medwin Healthcare CEO Debashis Bose said while addressing the virtual launch of the device.
The company will first dispatch the product to hospitals, clinics and other frontline warriors, he added.
"The production has already started and we are increasing it everyday. We are going to start despatching the product from the end of this month. We are planning to produce at least 1,30,000 devices within the next six months", Bose said.
The device is priced at Rs 19,999 inclusive of 18 per cent GST, he added.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751